Expression of costimulatory molecules on human retinoblastoma cells Y-79: functional expression of CD40 and B7H1.

PURPOSE To examine the expression of various costimulatory molecules on the human retinoblastoma cell line Y-79 and assess the functional roles of selected costimulatory molecules. METHODS Y-79 cells were incubated in the presence or absence of IFN-gamma, with or without irradiation (100 Gy). Expression of major histocompatibility complex (MHC) class I molecules, MHC class II, CD80, CD86, CD40, CD70, B7H1, B7DC, B7H2, OX40L, and 4-1BBL on Y-79 cells was measured by reverse transcription-polymerase chain reaction (RT-PCR) and flow cytometric analysis. The functional role of CD40-mediated interactions in modifying immune responses to Y-79 was assessed in vitro by using recombinant human CD40 ligand (rhCD40L). The costimulatory effect of B7H1-expressing IFN-gamma-treated Y-79 cells on proliferation of purified T cells was studied in Y-79/T-cell coculture experiments with a blocking anti-B7H1 monoclonal antibody (mAb). RESULTS CD40 and B7H2 were consistently detected on Y-79 cells by RT-PCR and flow cytometry. Cell surface expression of CD40 was upregulated on stimulation by IFN-gamma alone, radiation alone, and IFN-gamma combined with radiation. B7H1 expression was induced by IFN-gamma stimulation and increased further when irradiated Y-79 cells were stimulated by IFN-gamma. Treatment of Y-79 cells with rhCD40L enhanced cell surface expression of MHC class I and intercellular adhesion molecule (ICAM)-1 and also stimulated monocyte chemotactic protein (MCP)-1 production. Proliferative response of purified CD3+ T cells costimulated with IFN-gamma-stimulated Y-79 was significantly enhanced by the addition of anti-B7H1 mAb. CONCLUSIONS These results suggest that CD40 expressed on Y-79 plays an important role in augmenting antitumor immunity. In contrast, the expression of B7H1 on IFN-gamma-treated Y-79 cells contributes to the suppression of T cells. The dual effects of CD40 and B7H1 on Y-79 cells may contribute to positive or negative regulation of antitumor immune responses in human retinoblastoma.

[1]  A. A. Brian,et al.  Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing , 1994, Cancer Immunology, Immunotherapy.

[2]  A. Mackensen,et al.  Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy , 2005, Cancer Immunology, Immunotherapy.

[3]  C. Shields,et al.  CONTINUING CHALLENGES IN THE MANAGEMENT OF RETINOBLASTOMA WITH CHEMOTHERAPY , 2004, Retina.

[4]  G. Chantada,et al.  Results of a prospective study for the treatment of retinoblastoma , 2004, Cancer.

[5]  M. Weller,et al.  Expression of the B7‐related molecule ICOSL by human glioma cells in vitro and in vivo , 2003, Glia.

[6]  M. Weller,et al.  Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. , 2003, Cancer research.

[7]  J. Cheville,et al.  B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. , 2003, Cancer research.

[8]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[9]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  E. J. Friedman Immune modulation by ionizing radiation and its implications for cancer immunotherapy. , 2002, Current pharmaceutical design.

[11]  G. Freeman,et al.  PD‐1:PD‐L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL‐2 , 2002, European journal of immunology.

[12]  M. Madigan,et al.  Immunoglobulin superfamily expression in primary retinoblastoma and retinoblastoma cell lines. , 2002, Oncology research.

[13]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[14]  Ping Lu,et al.  B7H Costimulates Clonal Expansion of, and Cognate Destruction of Tumor Cells by, CD8+ T Lymphocytes In Vivo , 2001, The Journal of experimental medicine.

[15]  J. Gribben,et al.  Phase I study of recombinant human CD40 ligand in cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Chambers The expanding world of co-stimulation: the two-signal model revisited. , 2001, Trends in immunology.

[17]  J. Egen,et al.  CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. , 2001, Annual review of immunology.

[18]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[19]  F. Gejyo,et al.  Cancer immunogene therapy. , 2001, Archivum immunologiae et therapiae experimentalis.

[20]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[21]  A. van Elsas,et al.  Costimulatory wars: the tumor menace. , 2000, Current opinion in immunology.

[22]  F. Lee,et al.  Constitutive Expression of Functional 4-1BB (CD137) Ligand on Carcinoma Cells1 , 2000, The Journal of Immunology.

[23]  D. Taub,et al.  Role for CD40-CD40 ligand interactions in the immune response to solid tumours. , 2000, Molecular immunology.

[24]  F. Ionna,et al.  CD40 expressed on human melanoma cells mediates T cell co-stimulation and tumor cell growth. , 2000, International immunology.

[25]  G. Alvord,et al.  Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity1 , 2000, The Journal of Immunology.

[26]  S. Baldus,et al.  CD40 ligand-CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN-gamma. , 1999, Journal of immunology.

[27]  J. Simon,et al.  Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. , 1999, Cancer research.

[28]  J. O'Brien Alternative treatment in retinoblastoma. , 1998, Ophthalmology.

[29]  R. Flavell,et al.  CD40 and CD154 in cell-mediated immunity. , 1998, Annual review of immunology.

[30]  B. Ksander,et al.  Gene transfer of the CD80 costimulatory molecule into ocular melanoma cells using a novel episomal vector. , 1997, Investigative Ophthalmology and Visual Science.

[31]  Kazunori Kato,et al.  Adoptive transfer of cytotoxic T lymphocytes induced by CD86-transfected tumor cells suppresses multi-organ metastases of C1300 neuroblastoma in mice , 1997, Cancer Immunology, Immunotherapy.

[32]  M. Madigan,et al.  Human retinoblastoma: in vitro differentiation and immunoglobulin superfamily antigen modulation by retinoic acid , 1997, Cancer Immunology, Immunotherapy.

[33]  M. Madigan,et al.  Human retinoblastoma: a morphological study of apoptotic, leukocytic, and vascular elements. , 1997, Ultrastructural pathology.

[34]  F. Ferris,et al.  A new era for the treatment of retinoblastoma. , 1996, Archives of ophthalmology.

[35]  J. Suttles,et al.  The many roles of CD40 in cell-mediated inflammatory responses. , 1996, Immunology today.

[36]  T. Mosmann,et al.  The expanding universe of T-cell subsets: Th1, Th2 and more. , 1996, Immunology today.

[37]  E. Jaffee,et al.  A reassessment of the role of B7-1 expression in tumor rejection , 1995, The Journal of experimental medicine.

[38]  S. Rosenberg,et al.  Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. , 1995, Cancer research.

[39]  G. Gray,et al.  B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules. , 1995, Cancer gene therapy.

[40]  J. Gribben,et al.  Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. , 1994, Blood.

[41]  T. Springer,et al.  Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Mulé,et al.  Experimental and clinical studies of cytokine gene-modified tumor cells. , 1994, Human gene therapy.

[43]  P. Bruggen,et al.  Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.

[44]  S. Barez,et al.  Modulation of major histocompatibility complex class 1 genes in human retinoblastoma cells by interferons. , 1993, Investigative ophthalmology & visual science.

[45]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Arlen Tumor antigens. , 1981, The New England journal of medicine.

[47]  D. Albert,et al.  Characteristics of an established cell line of retinoblastoma. , 1974, Journal of the National Cancer Institute.